secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001213900-23-015546
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar reports Q4 2022 net loss $59.7M; cash $505M, runway through mid-2025
---------------------------------------------------------------------------

- Q4 2022 revenue $22.0M (down from $25.0M YoY); full-year revenue $92.1M (down from $101.9M).
- Q4 net loss $59.7M ($0.32 loss per share) vs $145.6M ($0.79) in Q4 2021; full-year net loss $368.2M ($1.97) vs $523.8M ($2.86).
- Cash and investments $505.0M at Dec 31, 2022, down from $798.8M; CEO expects runway through at least mid-2025 with additional cost cuts.
- R&D expense fell to $34.7M in Q4 (from $99.6M) due to wind down of bempegaldesleukin program; restructuring costs $11.6M in Q4.
- On Feb 23, 2023, announced Phase 2 topline data for rezpegaldesleukin in SLE; no Q4 earnings call held.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390023015546/0001213900-23-015546-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390023015546/ea174444-8k_nektartherap.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-015546

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer